Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1995; 25:1622-1626
© 1995 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pinto, Y.
Right arrow Articles by Schunkert, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pinto, Y.
Right arrow Articles by Schunkert, H

Deletion-type allele of the angiotensin-converting enzyme gene is associated with progressive ventricular dilation after anterior myocardial infarction. Captopril and Thrombolysis Study Investigators

YM Pinto, WH van Gilst, JH Kingma, and H Schunkert

Department of Clinical Pharmacology, University of Groningen, The Netherlands.

OBJECTIVES. This study sought to determine whether patients who are homozygous for the deletion (D)-type allele of the angiotensin-converting enzyme gene display augmented ventricular dilation after myocardial infarction. BACKGROUND. Recent evidence suggests that the deletion-type allele of the angiotensin-converting enzyme gene (DD genotype) is associated with an increased prevalence of myocardial infarction and myocardial hypertrophy. However, it is unknown whether the DD genotype is associated with adverse cardiac remodeling. To address this question we determined the genotype in patients enrolled in the Captopril and Thrombolysis Study (CATS), a prospective trial in which patients received either captopril or placebo during and after thrombolysis for a first anterior myocardial infarction. METHODS. Cardiac volume was determined by echocardiography immediately after thrombolysis and at 1-year follow-up. The genotype for the angiotensin-converting enzyme was determined in 96 patients. Norepinephrine levels were assessed during and immediately after thrombolysis. RESULTS. Immediately after thrombolysis, cardiac volume did not differ between genotype groups. However, at 1-year follow-up, both end-systolic and end-diastolic left ventricular volumes were significantly greater in the DD-genotype group. Norepinephrine increased to higher levels in the DD-genotype group that received placebo therapy. Captopril treatment effectively blunted both the norepinephrine increase and cardiac dilation in the DD-genotype group. CONCLUSIONS. This exploratory study suggests that homozygosity for the angiotensin-converting enzyme deletion-type allele is associated with augmented neurohumoral activation as well as augmented cardiac dilation after an acute anterior myocardial infarction, an effect that may be susceptible to angiotensin-converting enzyme inhibition.


This article has been cited by other articles:


Home page
Ann. Thorac. Surg.Home page
A. M. Feldman
The emerging role of pharmacogenomics in the treatment of patients with heart failure
Ann. Thorac. Surg., December 1, 2003; 76(6): S2246 - 2253.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
B. R. Palmer, A. P. Pilbrow, T. G. Yandle, C. M. Frampton, A. M. Richards, M. G. Nicholls, and V. A. Cameron
Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction
J. Am. Coll. Cardiol., March 5, 2003; 41(5): 729 - 736.
[Abstract] [Full Text] [PDF]


Home page
Eur J Heart FailHome page
D. J. van Veldhuisen and W. H. van Gilst
The pharmacological management of heart failure: too many treatments?
Eur J Heart Fail, January 1, 2003; 5(1): 5 - 8.
[Full Text] [PDF]


Home page
Eur Heart J SupplHome page
R.A de Boer and D.J van Veldhuisen
Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D111 - D116.
[Abstract] [PDF]


Home page
Eur Heart J SupplHome page
R. Ferrari, G. Guardigli, G. Cicchitelli, M. Valgimigli, E. Merli, O. Soukhomorskaia, and C. Ceconi
Angiotensin II overproduction: enemy of the vessel wall
Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A26 - A30.
[Abstract] [PDF]


Home page
Eur Heart JHome page
A Jeron, C Hengstenberg, S Engel, H Lowel, G.A.J Riegger, H Schunkert, and S Holmer
The D-allele of the ACE polymorphism is related to increased QT dispersion in 609 patients after myocardial infarction
Eur. Heart J., April 2, 2001; 22(8): 663 - 668.
[Abstract] [PDF]


Home page
HeartHome page
P P van Geel, Y M Pinto, A H Zwinderman, R H Henning, A J van Boven, J W Jukema, A V G Bruschke, J J P Kastelein, W H van Gilst, and G F BAXTER
Increased risk for ischaemic events is related to combined RAS polymorphism
Heart, April 1, 2001; 85(4): 458 - 462.
[Abstract] [Full Text]


Home page
CirculationHome page
G. J. Perry, T. Mori, C.-C. Wei, X. Y. Xu, Y.-F. Chen, S. Oparil, P. Lucchesi, and L. J. Dell'Italia
Genetic Variation in Angiotensin-Converting Enzyme Does Not Prevent Development of Cardiac Hypertrophy or Upregulation of Angiotensin II in Response to Aortocaval Fistula
Circulation, February 20, 2001; 103(7): 1012 - 1016.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. P. van Geel, Y. M. Pinto, A. A. Voors, H. Buikema, M. Oosterga, H. J. G. M. Crijns, and W. H. van Gilst
Angiotensin II Type 1 Receptor A1166C Gene Polymorphism Is Associated With an Increased Response to Angiotensin II in Human Arteries
Hypertension, March 1, 2000; 35(3): 717 - 721.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
A. Okamura, M. Ohishi, H. Rakugi, T. Katsuya, Y. Yanagitani, S. Takiuchi, Y. Taniyama, K. Moriguchi, H. Ito, Y. Higashino, et al.
Pharmacogenetic Analysis of the Effect of Angiotensin-Converting Enzyme Inhibitor on Restenosis After Percutaneous Transluminal Coronary Angioplasty
Angiology, October 1, 1999; 50(10): 811 - 822.
[Abstract] [PDF]


Home page
Eur Heart JHome page
M. Pfohl, M. Koch, S. Prescod, K.K. Haase, H.U. Haring, and K.R. Karsch
Angiotensin I-converting enzyme gene polymorphism, coronary artery disease and myocardial infarction. An angiographically controlled study
Eur. Heart J., September 2, 1999; 20(18): 1318 - 1325.
[Abstract] [PDF]


Home page
Cardiovasc ResHome page
Y. M Pinto and W. H van Gilst
The ACE gene polymorphism: the good, the bad and the ugly
Cardiovasc Res, July 1, 1999; 43(1): 23 - 24.
[Full Text] [PDF]


Home page
Eur J Heart FailHome page
M. Komajda, P. Charron, and F. Tesson
Genetic aspects of heart failure
Eur J Heart Fail, June 1, 1999; 1(2): 121 - 126.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Challah, E. Villard, M. Philippe, A. Ribadeau-Dumas, B. Giraudeau, P. Janiak, J.-P. Vilaine, F. Soubrier, and J.-B. Michel
Angiotensin I-Converting Enzyme Genotype Influences Arterial Response to Injury in Normotensive Rats
Arterioscler Thromb Vasc Biol, February 1, 1998; 18(2): 235 - 243.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Oosterga, A. A. Voors, P.-J. de Kam, H. Schunkert, Y. M. Pinto, J. H. Kingma, and W. H. van Gilst
Plasma Angiotensin-Converting Enzyme Activity and Left Ventricular Dilation After Myocardial Infarction
Circulation, June 17, 1997; 95(12): 2607 - 2609.
[Abstract] [Full Text]


Home page
Journal Watch CardiologyHome page
ACE Gene May Predispose to Post-MI Dilation
Journal Watch Cardiology, August 1, 1995; 1995(801): 14 - 14.
[Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement